NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · MID CAP
Axogen, Inc. AXGN
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$225.2M
▲ 20.2% vs FY2024
EPS · FY25
$-0.34
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-13.5%
Net margin · FY25
-7.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 225.2M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 7 cents on every revenue dollar this year.
Per share
USD -0.34
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-13.5%
Return on equity, FY2025
ROE
Operating margin-3.5%
Net margin-7.0%
Return on assets-7.4%
Each USD of equity lost 13 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+14.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+17.6%
+14.9%
+23.5%
+33.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+16.2%
Change, 10 years+57.4%
The share count grew 16% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 221.7M
total assets, end of FY2025
Total assetsUSD 221.7M
EquityUSD 128.8M
CashUSD 35.5M
Gross debtUSD 48.4M
Net debtUSD 12.8M
Current ratio5.11×
Net debt stands at 10% of equity.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.34
−0.23
−0.51
−0.69
−0.65
−0.60
−0.74
−0.60
−0.31
−0.47
−0.51
−0.99
−1.08
−0.85
−2.77
−8.35
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−13.5
−10.0
−22.1
−27.1
−22.9
−18.6
−20.9
−26.0
−52.1
−124.7
·
·
·
−581.0
·
·
Shares out B
0.05
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.03
0.03
0.03
0.02
0.02
0.01
0.01
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
62 of 62
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed